Matthew Bick

Matthew Bick

co-founder and Chief Executive Officer at Accipiter Biosciences
Seattle, Washington, United States

Matthew Bick is CEO and co-founder at Accipiter Biosciences. Previously, he served as Senior Director of Protein Sciences at Neoleukin Therapeutics and held senior scientist roles at Lyell Immunopharma and the University of Washington.

Accipiter Bio raises $10.5M more to speed AI-designed multi-target protein drugs, expanding clinical pipeline

Seattle biotech Accipiter Bio raised an additional $10.5 million from existing investors to accelerate development of AI-designed multi-target protein therapeutics and expand its team and clinical pipeline. The company, now 22 people strong and partnered with Pfizer and Kite/Gilead, will use the funds to advance three to four programs—focusing mainly on immunology alongside oncology—after emerging from stealth last year with $12.7 million.

Organizations

See all 10
  • Accipiter Biosciences co-founder and Chief Executive Officer 2023–present, Chief Executive Officer, CSO 2023 · current
  • Neoleukin Therapeutics Senior Director of Protein Sciences 2023, Director of Protein Sciences 2021–2023, Principal Scientist 2020–2021 · past
  • Lyell Immunopharma Senior Scientist / Project Lead 2019–2020 · past

Education

  • The Rockefeller University PhD, Biophysics · 2003–2010
  • University of Rochester BS, Microbiology · 1995–2000
  • University of North Carolina School of the Arts High School Diploma, Classical Guitar Performance, Composition · 1991–1995

Online